This is part 4 in “Promise or Peril: COVID-19 mRNA Vaccine Issues Series”
The pandemic has ended, but the introduction of the COVID-19 vaccines, which use mRNA technology, signifies the start of a new era in modern medicine. The lagging regulatory framework that the FDA cobbled together specifically for mRNA vaccine approval has set the stage for adverse events related to genetic therapies using this new technology. In this series, we reveal emerging concerns about mRNA injections related to the lipid nanoparticles, spike protein, and vaccine contamination as public documents are released.
Now, we turn to another problem—the cargo contained in the LNP capsules: the mRNA and its encoded spike protein. We introduce the inflammatory response to the spike protein and one of its subunit proteins and how they may contribute to serious adverse events such as myocarditis and blood clotting.
Dr. Rochelle Walensky, the former director of the U.S. Centers for Disease Control and Prevention (CDC), stated on “Good Morning America“ in June 2021 that myocarditis cases are ”really quite rare ... minor, self-limited, they generally resolve with rest and standard medications.” However, this assertion was made based on a preliminary review of 300 cases and before conducting long-term follow-up.
